Pharmaexcil wants WTO to take up UK ban issue

Published: 7-Jul-2014
Regulatory

Says MHRA ban of unlicensed herbal products in UK is violation of trade interest


Troubled by the plight of Ayurveda, Siddha and Unani (ASU) exporters in the wake of UK drug regulator the Medicines and Healthcare products Regulatory Agency's (MHRA) recent ban on the sale of unlicensed herbal products in UK, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) is seeking the intervention of the World Trade Organisation on this issue.

In a recent directive, the MHRA had stopped the immediate sale and use of all herbal medicines without registration or a product licence in Europe.

The Council has roundly condemned the stand taken by the MHRA, stating that the ban was 'a clear violation of trade interest', and a matter that the Commerce Ministry should bring to the attention of the WTO.

  • Companies:
  • MHRA
  • Pharmexcil
See more

You may also like

Regulatory

Biggest overhaul of trial regulation for 20 years

Read more
A series of new measures will be introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) with support from partners

Trending Articles

  1. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  2. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  3. Moderna senior executive to speak at the ISPE conference As Chief Technical Operations and Quality Officer, Andres is responsible for the supply of products required for the company’s preclinical and clinical development programmes
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Biggest overhaul of trial regulation for 20 years

A series of new measures will be introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) with support from partners
Regulatory

MHRA joins international partnerships to set global standards for medicines and medical devices regulation

The UK is set to play a greater international role in making sure medicines and medical devices are regulated safely and efficiently worldwide, the Medicines and Healthcare products Regulatory Agency (MHRA) has announced after being accepted as a full member of three international work-sharing partnerships
Regulatory

MHRA confirms registration of Avacta’s antigen lateral flow test

The company has ongoing commercial discussions with distributors and end user customers in countries that accept the CE mark for in vitro diagnostic products
Manufacturing

MHRA fully reinstates Bristol Labs GMP status

The company is now well-stocked for the shortages that may be brought about by Brexit
Regulatory

UK signs healthcare-focused Memorandum with Russia

The Medicines and Healthcare products Regulatory Agency has signed a Memorandum of Understanding with its Russian counterpart
Ingredients

Protak Scientific's enzymatic indicator gains MHRA support

The UK's Medicines and Healthcare products Regulatory Agency has agreed to form a focus group to discuss the use of enzymatic indicators for decontamination validation
Regulatory

UK clinical research post-Brexit

Dr Sheuli Porkess, Deputy Chief Scientific Officer of the ABPI here discusses the future of clinical research as the UK prepares to leave the EU
Subscribe now